Several ALK-TKIs have been approved for first-line therapy of ALK-positive NSCLC, including second-generation agents (alectinib, brigatinib, ensartinib and iruplinalkib in China) [68] and the third-generation TKI lorlatinib [70]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.